Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
February 13, 2025
APDN Reminds Shareholders to Vote Ahead of Special Meeting on February 14
February 11, 2025
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
January 10, 2025
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
January 8, 2025
ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-cell Therapy Produced from LineaDNA
December 18, 2024
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
December 17, 2024
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
December 16, 2024
APDN Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
October 30, 2024
Get Social